Agios Pharmaceuticals Financial Statements
NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Agios Pharmaceuticals revenue and earnings
In fiscal 2025, Agios Pharmaceuticals generated $54.0 million in revenue, up 48.0% from fiscal 2024, its 4th consecutive year of revenue growth. Agios Pharmaceuticals reported a net loss of $412.8 million, compared with net income of $673.7 million a year earlier. Gross margin was 88.3% (down from 88.6%) and operating margin -873.9%.
Diluted earnings per share came in at -$7.12, down from $11.64.
Summary generated from market data by MetaCap's automated system. Methodology
Agios Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.03M | 36.50M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M |
| Revenue growth (YoY) | +48.03% | +36.07% | +88.36% | — | — | -100.00% | +24.92% | +119.45% | -38.46% | +18.22% |
| Cost of Revenue | 6.34M | 4.17M | 2.88M | 1.70M | 0 | 0 | 1.32M | 1.40M | 0 | 0 |
| Gross Profit | 47.68M | 32.33M | 23.94M | 12.54M | 0 | 0 | 116.59M | 92.99M | 43.01M | 69.89M |
| Operating Expenses | 519.82M | 458.07M | 415.43M | 401.58M | 378.42M | 335.92M | 432.86M | 456.87M | 363.81M | 270.88M |
| Research & Development | 339.54M | 301.29M | 295.53M | 279.91M | 256.97M | 220.81M | 214.26M | 341.32M | 292.68M | 220.16M |
| Selling, General & Admin | 180.28M | 156.78M | 119.90M | 121.67M | 121.44M | 115.11M | 102.01M | 114.14M | 71.12M | 50.71M |
| Operating Income | -472.13M | -425.74M | -391.49M | -389.05M | -378.42M | -335.92M | -316.27M | -362.48M | -320.79M | -200.99M |
| Other Income (Expense) | 1.96M | 6.49M | 6.05M | 6.75M | 14.43M | 0 | 0 | — | — | — |
| Pretax Income | -413.80M | 717.97M | -352.09M | -231.80M | -356.51M | -329.31M | -301.41M | -346.03M | -314.67M | -198.47M |
| Income Tax | -1.02M | 44.24M | 0 | 0 | — | — | 0 | 0 | 0 | 0 |
| Net Income | -412.78M | 673.73M | -352.09M | -231.80M | 1.60B | -327.37M | -411.47M | -346.03M | -314.67M | -198.47M |
| Net Income growth (YoY) | -161.27% | — | — | -114.44% | — | — | — | — | — | — |
| EPS (Basic) | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 | -6.03 | -6.75 | -5.07 |
| EPS (Diluted) | -7.12 | 11.64 | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 | -6.03 | -6.75 | -5.07 |
| Shares Outstanding (Basic) | 57.97M | 56.81M | 55.65M | 54.79M | 60.45M | 69.00M | 59.99M | 57.42M | 46.59M | 39.13M |
| Shares Outstanding (Diluted) | 57.97M | 57.89M | 55.65M | 54.79M | 60.45M | 69.00M | 59.99M | 57.42M | 46.59M | 39.13M |
| EBITDA | -466.93M | -420.04M | -384.89M | -380.65M | -369.62M | -326.52M | -308.18M | -355.31M | -314.36M | -195.28M |
| Gross Margin | 88.26% | 88.59% | 89.26% | 88.03% | — | — | 98.88% | 98.52% | 100.00% | 100.00% |
| Operating Margin | -873.87% | -1166.47% | -1459.52% | -2732.07% | — | — | -268.22% | -384.03% | -745.84% | -287.57% |
| Net Margin | -764.01% | 1845.92% | -1312.63% | -1627.82% | — | — | -348.97% | -366.61% | -731.60% | -283.97% |
This table shows 10 annual periods of Agios Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AGIO's reporting calendar. What is a income statement?